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Abstract: Nanoemulsions (NE) are isotropic, dispersions of oil, water, surfactant(s) and cosurfac-
tant(s). A range of components (11 surfactants, nine cosurfactants, and five oils) were investigated as
potential excipients for preparation of ketorolac tromethamine (KT) ocular nanoemulsion. Diol cosur-
factants were investigated for the effect of their carbon chain length and dielectric constant (DEC), Log
P, and HLB on saturation solubility of KT. Hen’s Egg Test—ChorioAllantoic Membrane (HET-CAM)
assay was used to evaluate conjunctival irritation of selected excipients. Of the investigated surfac-
tants, Tween 60 achieved the highest KT solubility (9.89 ± 0.17 mg/mL), followed by Cremophor RH
40 (9.00 ± 0.21 mg/mL); amongst cosurfactants of interest ethylene glycol yielded the highest KT
solubility (36.84 ± 0.40 mg/mL), followed by propylene glycol (26.23 ± 0.82 mg/mL). The solubility
of KT in cosurfactants was affected by four molecular descriptors: carbon chain length, DEC, log P
and HLB. KT solubility was directly proportional to DEC and the HLB yet, inversely proportional to
carbon chain length and log P. All surfactants, except Labrasol ALF, were non-irritant. The majority
of cosurfactants were slightly irritant, butylene glycol was a moderate irritant, pentylene and hexy-
lene glycols were strong irritants. These findings will inform experiments aimed at developing NE
formulations for ocular administration of KT.
Keywords: nanoemulsion; ketorolac tromethamine; physicochemical properties; solubility; HET-
CAM assay
1. Introduction
Nanoemulsions (NE) are optically isotropic, colloidal dispersions with droplet sizes
ranging from 20 to 500 nm [1,2], mainly consisting of oil, surfactants (surfactants and cosur-
factants), and water [3,4]. They are characterized by a transparent/translucent appearance
and long-term stability which is mainly due to their extremely small droplet size [5,6].
NE systems have attracted increasing interest as potential carriers for drugs and biologics.
They are suitable carriers for both hydrophilic, lipophilic and amphiphilic drugs; may
control the release and protect susceptible compounds like antioxidants, vitamins and
shield them from external degradation triggers, such as light, pH, and temperature [7,8].
NEs are promising for ocular delivery of drugs, because of their ability to sustain
ocular drug release, which in turn improves ocular bioavailability, increasing corneal
absorption and drug permeation through membranes of the eye, and reducing the fre-
quency of drug administration, thus promoting better patient compliance [4,9]. The ocular
bioavailability of topically applied drugs is usually from (0.1–5%) mainly due to loss via
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nasolacrimal drainage as well poor corneal permeability [10,11]. NEs have attracted increas-
ing interest as a vehicle for topical ocular drug delivery through extending drug release,
prolonging precorneal retention, and increasing corneal permeability. Cationic NEs of
rifampicin with prolonged residence time on the eye have been prepared to combat ocular
tuberculosis [12], ibuprofen-loaded sustained-release NEs have been developed to act on
inflammatory components of dry eye disease [13]. NEs have been used as a biocompatible
carrier for ocular delivery of travoprost with improved pharmacodynamic and pharma-
cokinetic properties [14]; tacrolimus cationic NEs provided prolonged retention time which
is desirable in ocular inflammatory diseases [2]; moxifloxacin NE has been prepared with a
significant increase of bioavailability, reduced dosing frequency, and improved therapeutic
activity [15]; anti-glaucoma non-irritant NEs of brinzolamide have been prepared with
enhanced corneal permeability [16].
Surfactants and cosurfactants are essential components of NE systems. The surfactant
is adsorbed at the oil/water interface causing decreased surface tension, leading to droplet
size reduction, and NE formation [17]. The combination of surfactant and cosurfactant
used in the preparation of nanoemulsions is essential for producing the ultralow interfacial
tension needed to reduce droplet size to the nanometer range [5,18]. Using the lowest pos-
sible concentrations of surfactants and cosurfactants in the preparation of NEs is essential
to reduce the possibility of conjunctival irritation and toxicity to the cornea, and ocular
surface [19]. On most occasions, the use of surfactants alone is insufficient to reduce the
interfacial tension to levels required for NE formation, so a cosurfactant is used [20].
Cosurfactants have unique molecular characteristics; a short to medium hydrophobic
chain, weak amphiphilic nature, and terminal small hydrophilic group (such as hydroxyl
group characteristic of low molecular weight alcohols and diols). These properties increase
the tendency of cosurfactants to interact with surfactant monolayers at interfaces, per-
turbing the packing and long-range order of surfactant molecules and promoting better
interface fluidity and curvature in favor of NE formation. Furthermore, the balanced
amphiphile nature of these molecules promotes their selective partitioning between phases,
changing their composition and thereby their relative hydro/lipophilicity of the immiscible
phases to improve better miscibility [21].
Non-ionic surfactants are more suited for ocular preparations due to their lower ocular
toxicity and better tolerability; the tendency of surfactants to cause ocular irritation is as
follows: non-ionic < Zwitterionic < anionic < cationic [22]. Furrer et al. reported similar
findings when they investigated eight different surfactants for ocular irritation in both
rabbit and mice models [23].
The physicochemical properties of surfactants and cosurfactants such as dielectric
constant (DEC), the logarithm of the octanol/water partition coefficient (log P), molecular
weight, carbon-chain length, and branching and carbon content weight percent (C%)
may impact the formation of NE and their ability to solubilize drugs. The hydrophile-
lipophile balance value (HLB) is regarded as an empirical guide for the selection of a good
surfactant and cosurfactant suitable for NE preparation [20,24,25]. The percentage weight
of hydrophilic and lipophilic moieties of a surfactant molecule is important for determining
the behavior of the surfactant [26]. The higher the HLB of a surfactant, the higher its
aqueous solubility [22]. Log P is a measure of lipophilicity [27], a linear relationship
has been found between the lipophilicity as a function of log P and the tendency for
solubilization [25].
Ketorolac tromethamine (KT) (Figure 1) is a first-generation, non-steroidal anti-
inflammatory drug with potent analgesic activity; it exists in three crystalline forms with
equal aqueous solubility. It acts by non-specific inhibition of prostaglandin synthesis
through the competitive blocking of cyclooxygenase (COX) enzyme. Ketorolac is effective
in management of postoperative inflammation and seasonal allergic conjunctivitis, without
affecting herpes simplex, fungal and bacterial infection of the eye [28,29]. It is commercially
available as a sterile aqueous solution (0.4–0.5% w/v) for use as eye drops, where it is
applied topically up to four times a day. The need for multiple application of KT eye
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drops along with their undesirable side effects of severe burning sensation, stinging and
itching of the eye results in poor patient adherence, often leading to failure of pain and
inflammation management after cataract or corneal refractive surgery [30].
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Many attempts have been made to develop KT formulations with improved efficacy.
Poloxamer based in situ gels with sustained release properties and enhanced bioavailabil-
ity [31]; chitosan-based nanoparticles with increased ocular retention time and enhanced
permeability [32]; and poloxamer 407-based nanocellulose grafted collagen (CGC) to
sustained KT release are some examples [30]. However, none of the aforementioned ap-
proaches addressed the patient’s discomfort associated with the topical ocular application
of KT eye drops, nor did they improve patient compliance. KT NE could serve to prolong
ocular residence time, which would enable the reduction of the required dose [13]. The KT
dose reduction along with the emollient/lubricant characteristics of the proposed NE for-
mulation is likely to help minimize the burning and stinging associated with conventional
KT eye drops which would hopefully improve patient acceptability [33].
This manuscript reports on studies aimed at screening a range of non-ionic surfac-
tants, cosurfactants, and oils with emphasis on their suitability for use in developing NE
formulation for topical ocular ad inistration of KT.
2. Materials and Methods
2.1. Materi ls
Ketorolac tromethamine (KT) was obtained from TCI chemicals (Tokyo, Japan). Fer-
tilized white horn eggs were purchased from Heath Farm (Fakenham, UK). Transcutol
P, Labrafac PG, Labrafac lipophile WL 1349, Labrafil M 1944 CS, Labrafil M 2125 CS,
Labrafil M 2130 CS, and Labrasol ALF were received as a gift from Gattefosse SAS (Leon,
France). Tween 20, Tween 60, Tween 80, Span 20, triacetin, ethyl oleate, dimethyl isosorbide,
ethylene glycol, propylene glycol and isopropyl myristate were obtained from ACROS
organics (Fair Lawn, NJ, USA). Cremophor RH 40, Cremophor EL, butylene glycol, penty-
lene glycol, hexylene glycol, Span 80, 2-butyl-2-ethyl-1,3-propanediol, (2,3-butanediol),
NaOH were purchased From Sigma-Aldrich (Taufkirchen, Germany). Sodium chloride,
sodium bicarbonate, and calcium chloride dehydrate were from Fisher Scientific UK Ltd.
(Loughborough, UK). Other chemicals used were of analytical grade.
2.2. Methods
2.2.1. Identification and Selection of Potential Surfactants and Cosurfactants Based on HLB
Calculations
The choice of suitable excipients is essential in the development of NE. For this study,
the selection of excipients was based on reviewing published literature, and all excipients
were checked for suitability of use in ophthalmic preparations. The HLB system can be
u d as a systemat c method for narrowing down candidates and a selection of potential
surfactants and cosurfac ants for preparation of a stable NE [34].
The HLB value for all surfactants an cosurfactants w s etermined by the Davies
method [35], in which the HLB value is directly calculated from the chemical formula of the
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molecule (Equation (1)), and the method specifies the group number for each constituent
of the molecule, the calculated values are then compared with reported values.
HLB = Σ (hydrophilic group numbers) − n (group number per CH2 group) + 7 (1)
in which, n is the number of -CH2- groups in the surfactant molecule.
Nonionic surfactants are often used for NE preparations because; they are less affected
by changes in pH and ionic strength, they possess a high degree of compatibility with other
components, they have a good physicochemical stability, and low toxicity [36]. In this study,
a group of non-ionic surfactants were selected (Tween 20, Tween 60, Tween 80, Span 20,
Span 80, Cremophor RH 40, Cremophor EL, Labrasol ALF, Labrafil M 2125 CS, Labrafil
M 1944 CS, and Labrafil M 2130 CS) with different HLB values. Cosurfactants included
(ethylene glycol, propylene glycol, butylene glycol, pentylene glycol, hexylene glycol,
dimethyl isosorbide, 2-butyl-2-ethyl-1,3-propanediol, (2,3-butanediol), and Transcutol P),
while triacetin, ethyl oleate, Labrafac PG, Labrafac lipophile WL 1349, and isopropyl
myristate were used as oils.
2.2.2. Determination of Selected Properties and Molecular Descriptors of Cosurfactants
The physicochemical properties of selected cosurfactants (diols) with different carbon
chain lengths were studied depending on six descriptors [carbon chain length, logarithm of
partition coefficient in octanol/water (log P), dielectric constant (DEC), molecular weight
(Mwt) and carbon content weight percent (C%).
2.2.3. Saturation Solubility Studies of Ketorolac Tromethamine (KT) in Surfactants,
Cosurfactants, and Oils
The saturation solubility of ketorolac tromethamine (KT) was determined by adding an
excess amount of drug powder to 5 mL of each oil, surfactant, cosurfactant, deionized water,
and simulated tear fluid (STF), all of which were kept in tightly closed small glass tubes.
Then these tubes were placed in a shaking water bath at 25 ± 0.5 ◦C for 72 h. After this
time, the samples were filtered by using a syringe filter membrane (SLGP033RS Millipore
Millex-GP Syringe Filter Unit, 0.22 µm, polyether sulfone (PES)). Once the samples had
been filtered, the solubility was determined at the λ max of KT (322 nm) using a UV-visible
spectrophotometer (Jenway 7315 Spectrophotometer, Bibby Scientific Ltd., Stone, UK).
The filter was subjected to multiple washes followed by analysis to quantify any traces
of KT being adsorbed on the filter membrane. No evidence of any KT adsorption to the
filter membrane was found. The STF was made using 0.67 g sodium chloride, 0.20 g
sodium bicarbonate, and 0.008 g of calcium chloride dehydrate to 100 mL distilled water
q.s. (pH 7.4) [37].
2.2.4. Conjunctival Irritation of Surfactants, Cosurfactants, and Oils by the HET-CAM
Assay
Freshly collected fertilized hen eggs (white horn) were incubated for three days at
(37 ± 0.5 ◦C) and at a relative humidity of (40 ± 4%). During incubation, the eggs were
kept horizontal inside the trays and were rotated daily to give the embryo a good position
and prevent its attachment to one side of the egg. On day three, the eggs were sprayed
with methylated spirit and their shells were carefully crack-opened and poured into a
growing chamber made of a glass beaker with a piece of cellophane membrane (Glad Wrap)
on it. After that, the eggs were examined for embryo viability with an intact CAM and
yolk. Eggs with dead embryos, or broken yolk sacs were discarded, others were further
incubated [38]. On day 10, a specified amount (200 µL) of each surfactant, cosurfactant,
and oil was placed on the CAM and tested for any sign of irritation. NaOH (0.1 M) and
normal saline were used as positive (strong irritant) and negative (non-irritant) controls
respectively. After time intervals of 0.5, 2, and 5 min, the blood vessels and capillaries were
examined for any irritant effects like hyperemia, hemorrhage, and coagulation. A time-
dependent numerical score (Table 1) was used to give a single value (cumulative score)
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was obtained after the summation of the three irritant response scores. This value was
interpreted as the irritation potential of the test substance (Table 2).
Table 1. Time-dependent numerical scores for each of the three irritant responses [39].
Effect Score
Time (min) 0.5 2.0 5.0
Hyperemia 5 3 1
Hemorrhage 7 5 3
Clotting or
Coagulation 9 7 5
Table 2. Irritation potential interpretation of various cumulative scores [39].






Data was represented as a mean value minus/plus standard deviation (±SD) of three
independent experiments. Student’s tests and one-way analysis of variance (ANOVA)
were used for a statistical significance calculation using the software GraphPad Prism
(GraphPad Prism software, Inc., San Diego, CA, USA). p values < 0.05 were considered
as significant.
3. Results and Discussion
3.1. Identification and Selection of Potential Surfactants and Cosurfactants Based on
HLB Calculations
The HLB system provides a systematic approach for selecting mixtures of surfactants
and cosurfactants for NE preparation; matching HLB values of surfactants will promote the
formation of a physically stable NE [26]. Low values of HLB indicate lipophilicity or less
water solubility, while higher values indicate more water-solubility or hydrophilicity [20].
Many researchers have used HLB values during the early stages of formulation develop-
ment to aid in the selection of appropriate surfactants for a particular purpose [24,40].
The HLB value takes into account the contribution of hydrophilic and lipophilic parts
of the surfactant molecule [34]. The type of NE formed could be predicted from the HLB
values of surfactants and cosurfactants used in their formulation. HLB values from (3–6) are
more likely to produce water in oil (w/o) NEs, while oil in water (o/w) type is more likely
to be formed in the range of (8–18). The HLB value for all surfactants and cosurfactants
of interest in this study was determined according to Davies’ method and compared to
literature-reported values (Table 3).
3.2. Determination of Physicochemical Properties and Molecular Descriptors of Selected
Cosurfactants
The physicochemical properties of cosurfactants can appreciably affect their per-
formance and ability to promote NE formation, stabilization, and performance as drug
delivery systems [43]. The calculated physicochemical properties of selected cosurfactants
would affect their ability to promote NE formation of a particular type (o/w or w/o). As out-
lined before, cosurfactants exert a dual effect, interfacial and bulk effects. The values of the
selected molecular descriptors are shown in Table 4. Log P is a measure of the lipophilicity
of the unionized part of the cosurfactant in a specific pH range at a particular tempera-
ture [44]. Increasing the percentage of carbon (C%) in the backbone of the cosurfactant
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was associated with higher values of log P, lower dielectric constant (DEC), and larger
molecular weight (Mwt). The molecular descriptors studied for these cosurfactants are
critical to inform their choice for future phase-behavior studies in addition to their impact
on the solubility of the hydrophilic drug of interest KT.
Table 3. Selected surfactants and cosurfactants with their calculated and reported HLB values.
Surfactants & Cosurfactants Calculated HLB Reported HLB
Tween 20 16.67 16.70 [34]
Tween 60 13.82 14.90 [34]
Tween 80 13.82 15.0 [34]
Span 20 8.67 8.60 [34]
Span 80 5.82 4.30 [34]
Cremophor RH 40 15.65 15.0 [41]
Cremophor EL 14.0 13.0 [41]
Labrasol ALF 14.69 14.0 [40]
Labrafil M2125 CS 5.20 4.0 [40]
Labrafil M1944 CS 5.20 4.0 [40]
Labrafil M2130 CS 5.20 4.0 [40]
Ethylene glycol 9.85 9.85 [42]
Propylene glycol 9.37 9.38 [42]
Butylene glycol 8.90 8.90 [42]
Pentylene glycol 8.42 8.43 [19]
Hexylene glycol 7.95 7.95 [19]
Dimethyl isosorbide 8.40 -
2-Butyl-2-ethyl-1,3-
propanediol 6.52 -
2,3-Butanediol 8.90 8.90 [42]
Transcutol P 8.61 4.20 [40]










(1,2-ethanediol) C2H6O2 2 −1.69 41.4 62.07 38.70
Propylene glycol
(1,2-propanediol) C3H8O2 3 −1.34 32.0 76.10 47.35
Butylene glycol
(1,2-butanediol) C4H10O2 4 −0.74 28.8 90.12 53.30
Pentylene glycol
(1,2-pentanediol) C5H12O2 5 −0.27 18.2 104.15 57.66
Hexylene glycol
(1,2-hexanediol) C6H14O2 6 0.58 7.70 118.17 60.98
1 C No; carbon atom number, log P; logarithm of partition coefficient in octanol/water, DEC; dielectric constant,
Mwt; molecular weight, C%; carbon content weight percent.
3.3. Saturation Solubility Studies of Ketorolac Tromethamine in Surfactants, Cosurfactants,
and Oils
For developing a successful and stable NE, the saturation solubility of the drug in
all excipients is one of the most important criteria [45]. The saturation solubility of KT
was determined in all excipients of interest (Table 5). Of the investigated surfactants
Tween 60 achieved the highest KT solubility (9.89 ± 0.17 mg/mL), followed by Cre-
mophor RH 40 (9.00 ± 0.21 mg/mL), Tween 20 (7.30 ± 0.20 mg/mL), and Labrasol ALF
(6.64 ± 0.13 mg/mL). Whilst one would expect a correlation between HLB of surfactant
and KT solubility, this was not the case. However, the difference in KT solubility is sig-
nificant (p < 0.05) amongst all surfactants. Nevertheless, it is worthwhile noting that, the
average solubility of KT in high HLB surfactant (HLB >13) is around 6.78 mg/mL whereas
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for the low HLB surfactant (HLB < 9) it is around 1.96 mg/mL. The differences in HLB
between Tween 20, 60, and 80 are insignificant (p > 0.05). However, KT solubility difference
are significant (p < 0.05). One possible explanation for the unusual behavior of Tween
80 could be due to the nature of the fatty acid residue being unsaturated whereas both
Tween 60 and 20 are based on saturated fatty acids [22]. The difference in HLB value
between the Cremophor EL and Cremophor RH40 is insignificant, yet the difference in KT
solubility is. This observation is similar to what was observed with Tweens. One possible
explanation could be due to the difference in the molecular structure where Cremophor
EL has unsaturation and less polyethylene oxide leading to a higher packing parameters.
In both molecules, the unsaturation resulted in less solubility of KT, this could be related to
the effect of chain unsaturation on packing parameters, where less intermolecular contact
is likely [46]. Other molecular descriptors such as log P, DEC are also known to impact
ionization potential and water/oil partitioning, respectively. Both could impact solubility
of KT in a particular cosurfactant.
Table 5. Saturation solubility of KT in different excipients (surfactants, cosurfactants, oils, deionized







Tween 20 7.30 ± 0.20 Pentylene glycol 16.04 ± 0.95
Tween 60 9.89 ± 0.17 Hexylene glycol 10.36 ± 0.85
Tween 80 3.82 ± 0.41 Dimethyl isosorbide 4.54 ± 0.55
Span 20 5.01 ± 0.27 2-butyl-2-ethyl-1,3-propandiol 9.55 ± 0.60
Span 80 3.18 ± 0.37 2,3-butanediol 22.93 ± 0.24
Cremophor RH 40 9.00 ± 0.21 Transcutol P 13.32 ± 0.11
Cremophor EL 4.03 ± 0.38 Triacetin 0.06 ± 0.001
Labrasol ALF 6.64 ± 0.13 Ethyl Oleate 0.04 ± 0.01
Labrafil M2125 CS 0.48 ± 0.06 Labrafac PG 0.01 ± 0.002
Labrafil M1944 CS 0.33 ± 0.03 Labrafac lipophileWL 1349 0.01 ± 0.01
Labrafil M2130 CS 0.80 ± 0.04 Isopropyl Myristate 0.01 ±0.02
Ethylene glycol 36.84 ± 0.40 Simulated tear fluid 199.2 ± 7.40
Propylene glycol 26.23 ± 0.82 Deionized water 217.1 ± 1.13
Butylene glycol 21.09 ± 1.22
1 Mean ± SD, n = 3.
Amongst the investigated cosurfactants, Ethylene glycol resulted in the highest solubil-
ity for KT (36.84± 0.40 mg/mL), followed by propylene glycol (26.23± 0.82 mg/mL), buty-
lene glycol (21.09± 1.22), pentylene glycol (16.04± 0.95), and hexylene glycol (10.36± 0.85).
Butylene glycol (1,2-butanediol) and its isomer 2,3-butylene glycol (2,3-butanediol) had
same HLB value and close physicochemical properties; yet a slight difference between
their KT solubility (which was not significant (p > 0.05). On the other hand, 2-butyl-2-
ethyl-1,3-propandiol, and dimethyl isosorbide had significantly different (p < 0.05) HLB
values (6.52 and 8.4, respectively) as well as significant difference (p < 0.05) in KT solubility.
Such difference could be related to the more drastic variation in molecular shape and
physicochemical properties that could impact solubility [47]. Furthermore, dimethyl isosor-
bide has more steric hindrance than 2-butyl-2-ethyl-1,3-propandiol, this could potentially
lead to a decrease in the solubility of KT [48].
Transcutol P promoted a relatively high solubility (13.32 ± 0.11 mg/mL) of the drug.
To avoid any potential precipitation and phase separation in NE formulations, maximum
solubility of the drug is needed inside the oil [45]. On the other hand, reduced solubility of
a highly water-soluble drug (like KT) could serve the purpose of delaying drug release,
hence providing an opportunity to modulate and prolong the release. Of the investigated
oils, Triacetin showed the highest solubility for KT (0.06 ± 0.001 mg/mL), which could
be related to the existence of three ester groups that impart some hydrophilic nature to
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the molecule, followed by ethyl oleate (0.04 ± 0.01 mg/mL), which is a long chain (C20)
unsaturated fatty acid ester. Also, no significant difference (p > 0.05) was seen when the
saturation solubility of the drug was tested in simulated tear fluid (STF) and deionized
water which was the highest relative of all excipients.
Effect of Cosurfactants Carbon Chain Length, DEC, log P, and HLB Value on the Solubility
of Ketorolac Tromethamine
The solubility of KT decreased significantly (p < 0.05) as the number of backbone
carbon atoms increased from 2 to 6 (Figure 2a); this could be related to the physicochemical
properties of the drug and the cosurfactants used. A relationship has been established
between solubility and DEC. DEC is an indirect measure of the ionization potential of the
molecule as well as the tendency of a particular solvent to promote such ionization [49].
Changes in dielectric constant have a great effect on the solubility of electrolytes (like KT) in
particular; higher DEC causes more ionization of KT, hence more solubility [50]. Increasing
DEC of cosurfactants caused a significant (p < 0.05) increase in solubility of KT (Figure 2b).
log P is regarded as an essential parameter for predicting solubility [51]. Many studies
demonstrate increasing solubility of drugs with decreasing lipophilicity (log P) [51,52].
The dependence of the solubility of KT on log P of cosurfactants is shown in Figure 2c.
Furthermore, the HLB value could be used as an indication of the solubility behavior, lower
HLB values indicate higher lipophilicity while higher values indicate more hydrophilicity,
hence more solubility [26]. From the results, it was seen that as the cosurfactants carbon
atom numbers (carbon chain length) increased from two atoms (ethylene glycol) to six atoms
(hexylene glycol), the HLB value decreased significantly (p < 0.05) (Figure 2d). A previous
study reports that with 1,2-alkandiol molecules increasing carbon chain length imparts more
lipophilicity to the molecule thus increasing carbon chain length results in a decrease in HLB
value [22]. The investigated alkanediols are the only group of cosurfactant molecules that
fulfilled the definition of “homologous series” where there is a small and incremental change
in molecular structure (one carbon atom at a time). The position of the two hydroxyl groups
remained constant (1,2 diols). This gradual and systematic change in molecular structure
allowed clear and unambiguous correlation with molecular descriptors and KT solubility as
well as molecular structure. On the other hand, none of the other surfactants, cosurfactants,
and oils investigated in this study had such a close molecular structure similarity. Generally,
in this study the excipients with higher HLB values (hydrophilic) were able to dissolve KT
to a greater extent than those with lower HLB values (Tables 3 and 5), which is due to the
hydrophilic nature of the drug (aqueous solubility is >200 mg/mL, Pka = 3.5, log P = 2.28).
3.4. Conjunctival Irritation of Surfactants, Cosurfactants, and Oils Determined by the
HET-CAM Assay
Ocular irritation is likely to be an issue in NE formulation development, due to
their relatively high surfactant and cosurfactant content. Ocular irritation is a source of
patient discomfort where it could lead to discontinuation of the medication [53]. The HET-
CAM assay has been used for the evaluation of conjunctival responses to test substances.
The chorioallantois is a well-accepted ex vivo model of the human conjunctiva [32,54].
The vascular and inflammatory responses of CAM to injury are immediate. Those responses
are similar to those produced by the human conjunctival tissue [55]. The vascular response
of the CAM surface to the negative control substance (normal saline) and positive control
substance (NaOH) are shown in Figure 2. Normal saline showed no effect on the surface of
the CAM (Figure 3a) while NaOH produced a very strong irritation response with complete
blood vessel lysis, clotting, and coagulation (Figure 3b).
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Table 6 summarizes the conjunctival irritation potential results of all the surfactants,
cosurfactants, and oils of interest as determined using the HET-CAM assay. Tweens and
spans were shown to be practically non-irritant. It has been previously reported that
formulations containing Spans possessed good ocular tolerability with a non-irritant ef-
fect [22]. Cremophor EL, Cremophor RH 40, Labrafills, Triacetin, and Labrafac lipophile
WL 1349 were also deemed to be non-irritant. Cremophor EL has been previously re-
ported to be safe to the eye in concentrations up to 30% (w/w) [56]. Labrasol ALF has
been reported to be non-irritant at concentrations of 0.5–3% (v/v) and slightly irritant at
higher concentrations [57].
1,2-alkanediols with 2–3 carbon chain length were reported to be only slightly irritant,
1,2-butanediol was a moderate irritant, while carbon chain length (5–8) were strong irri-
tants [58]. In this study, propylene glycol showed slight lysis of blood vessels and thus a
slight irritant effect when used alone, butylene glycol was a moderate irritant, pentylene
glycol and hexylene glycol showed a strong irritant effect and caused severe damage of
blood vessels. It has been previously reported that undiluted propylene glycol solutions
may cause weak conjunctival redness, while diluted solutions were non-irritant [59]. The
gradual and systematic change in molecular structure of 1,2 alkanediol (homologous se-
ries) allowed clear and unambiguous correlation between molecular structure and ocular
irritation. Transcutol P was deemed to be slightly irritant, this result is in agreement with
those obtained by Butt et al. [55] and Liu et al. [60]. Triacetin and Labrafac lipophile WL
1349 were practically non-irritant, while ethyl oleate, Labrafac PG, and isopropyl myristate
were slight irritant.
Table 6. Ocular irritation potential calculated from the cumulative scores of the vascular responses of the CAM.
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4. Conclusions
A range of nonionic surfactants, cosurfactants and oils were screened for the suitability
as NE excipients for ocular administration of KT. The solubility of KT was found to be
affected by the physicochemical properties of surfactants and cosurfactants (carbon chain
length, HLB value, dielectric constant, and log P). Only homologous series of alkanediols
(C2–C6) showed a clear correlation between calculated molecular descriptors and KT
solubility. This systematic change in molecular structure allowed clear and unambiguous
correlation of molecular descriptors and KT solubility as well as molecular structure
and ocular irritation. On the other hand, none of the other surfactants, cosurfactant and
oils investigated in this study had such a close molecular structure similarity, hence the
lack of correlation between molecular descriptors and KT solubility as well as molecular
structure and ocular irritation. All the investigated nonionic surfactants were deemed to be
practically non-irritant except for Labrasol ALF, which was found to be slightly irritant.
All cosurfactants investigated were found to be irritant, albeit to varying extents. Of the
investigated excipient and considering both KT solubility and ocular irritation results;
Tween 60, Cremophor RH 40 and Tween 20 would be the surfactants to be taken forward
to use in developing NE formulation for ocular KT delivery. As for studied cosurfactants,
ethylene glycol and propylene glycol would be the candidates of choice, albeit being
slightly irritant. Triacetin and Labrafac lipophile WL 1349 would be the oils of choice.
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